companies

Phialogics

Founded 2021
Employees 5+
Primary contact
Swiss Innovation Park Basel Area
Hegenheimermattweg 167A
4123 Allschwil
Switzerland
Links
https://www.phialogics.com/
Diseases & Conditions
Sections
A spin-off from from Fraunhofer Institute for Immune Pathology and Immune Tolerance, Phialogics is a preclinical biotech company specializing in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Current lead candidates are genetically engineered monospecific IgVs with the potential to be expanded to bispecific therapeutics to achieve selectivity for inflamed tissue and/or disease-causing immune cells. This strategy can potentially provide new solutions for patients with autoimmune diseases by rebalancing their overactive immune response in selected organs and tissue.
Founded 2021
Employees 5+
Primary contact
Swiss Innovation Park Basel Area
Hegenheimermattweg 167A
4123 Allschwil
Switzerland
Links
https://www.phialogics.com/
Diseases & Conditions
Sections

Funding 💰

Total €600K
Last round 🔗 €600K
Pre-Seed
April 20, 2023.
Select investors High-Tech Grunderfonds (HTGF)

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Innovative concept: Phialogics' innovative concept is the protein engineering of receptor ligands to generate signaling agonists that modulate the activity of immune cells.
  • Phage display: The company uses its proprietary phage display platform with a built-in selection for folding and stability.
  • Help in sepsis: According to the company, its modified antibody receptor domains could also be used to prevent multi-organ failure in sepsis, in which PD-L1 overexpression has been shown to induce regulatory T cells that mitigate the overshooting proinflammatory immune reaction in liver cells.
Last update: May 16, 2023